Back to Search Start Over

Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids

Authors :
Kloess, Stephan
Chambron, Nicole
Gardlowski, Tanja
Weil, Sandra
Koch, Joachim
Esser, Ruth
von Strandmann, Elke Pogge
Morgan, Michael A.
Arseniev, Lubomir
Seitz, Oliver
Koehl, Ulrike
Kloess, Stephan
Chambron, Nicole
Gardlowski, Tanja
Weil, Sandra
Koch, Joachim
Esser, Ruth
von Strandmann, Elke Pogge
Morgan, Michael A.
Arseniev, Lubomir
Seitz, Oliver
Koehl, Ulrike
Publication Year :
2015

Abstract

Immunosuppressive factors, such as soluble major histocompatibility complex class I chain-related peptide A (sMICA) and transforming growth factor beta 1 (TGF-beta(1)), are involved in tumor immune escape mechanisms (TIEMs) exhibited by head and neck squamous cell carcinomas (HNSCCs) and may represent opportunities for therapeutic intervention. In order to overcome TIEMs, we investigated the antibody-dependent cellular cytotoxicity (ADCC), cytokine release and retargeted tumor infiltration of sMICA-inhibited patient NK cells expressing Fc gamma receptor Illa (Fc gamma RIlla, CD16a) in the presence of cetuximab, an anti-epidermal growth factor receptor (HER1) monoclonal antibody (mAb). Compared to healthy controls, relapsed HNSCC patients (n = 5), not currently in treatment revealed decreased levels of circulating regulatory NK cell subsets in relation to increased cytotoxic NK cell subpopulations. Elevated sMICA and TGF-beta(1) plasma levels correlated with diminished TNF alpha and IFN-gamma release and decreased NKG2D (natural killer group 2 member D)-dependent killing of HNSCC cells by NK cells. Incubation of IL-2-activated patient NK cells with patient plasma containing elevated sMICA or sMICA analogs (shed MICA and recombinant MICA) significantly impaired NKG2D-mediated killing by down-regulation of NKG2D surface expression. Of note, CD16 surface expression levels, pro-apoptotic and activation markers, and viability of patient and healthy donor NK cell subpopulations were not affected by this treatment. Accordingly, cetuximab restored killing activity of sMICA-inhibited patient NK cells against cetuximab-coated primary HNSCC cells via ADCC in a dose dependent manner. Rapid reconstitution of anti-tumor recognition and enhanced tumor infiltration of treated NK cells was monitored by 24 h co-incubation of HNSCC tumor spheroids with cetuximab (1 mu g/ml) and was characterized by increased IFN-gamma and INF alpha. secretion. This data show that the impaired NK cell-d

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1247370212
Document Type :
Electronic Resource